Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol

被引：0

作者：

Jennifer E. Lambert

Jill A. Parnell

Bertus Eksteen

Maitreyi Raman

Marc R. Bomhof

Kevin P. Rioux

Karen L. Madsen

Raylene A. Reimer

机构：

[1] University of Calgary,Faculty of Kinesiology

[2] Mount Royal University,Health and Physical Education

[3] University of Calgary,Snyder Institute for Chronic Diseases, Health Research and Innovation Center

[4] University of Calgary,Division of Gastroenterology and Hepatology, Department of Medicine

[5] University of Calgary,Department of Microbiology and Infectious Diseases

[6] University of Alberta,Division of Gastroenterology, Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, 7–142 Katz Group–Rexall Centre

[7] Department of Biochemistry & Molecular Biology,undefined

[8] Cumming School of Medicine,undefined

来源：

BMC Gastroenterology | / 15卷

关键词：

Prebiotic fiber; Gut microbiota; Fatty liver; Weight loss; Fibrosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol
Lambert, Jennifer E.
Parnell, Jill A.
Eksteen, Bertus
Raman, Maitreyi
Bomhof, Marc R.
Rioux, Kevin P.
Madsen, Karen L.
Reimer, Raylene A.
BMC GASTROENTEROLOGY, 2015, 15
[2] Gut microbiota and non-alcoholic fatty liver disease
Gkolfakis, Paraskevas
Dimitriadis, George
Triantafyllou, Konstantinos
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (06) : 572 - 581
[3] Gut microbiota and non-alcoholic fatty liver disease
Abenavoli, Ludovico
Procopio, Anna C.
Scarpellini, Emidio
Polimeni, Natale
Aquila, Isabella
Larussa, Tiziana
Boccuto, Luigi
Luzza, Francesco
MINERVA GASTROENTEROLOGY, 2021, 67 (04): : 339 - 347
[4] Gut microbiota and non-alcoholic fatty liver disease
Paraskevas Gkolfakis
George Dimitriadis
Konstantinos Triantafyllou
Hepatobiliary & Pancreatic Diseases International, 2015, 14 (06) : 572 - 581
[5] Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, John Willy
Konopski, Zbigniew
Eggesbo, Heidi Beate
Von Volkmann, Hilde Loland
Raschpichler, Gabriele
Bjoro, Kristian
Haaland, Terese
Loberg, Else Marit
Birkeland, Kare
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 853 - 860
[6] Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease
Shen, Feng
Zheng, Rui-Dan
Sun, Xing-Qiang
Ding, Wen-Jin
Wang, Xiao-Ying
Fan, Jian-Gao
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (04) : 375 - 381
[7] Non-alcoholic fatty liver and the gut microbiota
Bashiardes, Stavros
Shapiro, Hagit
Rozin, Shachar
Shibolet, Oren
Elinav, Eran
MOLECULAR METABOLISM, 2016, 5 (09): : 782 - 794
[8] Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial
de Avelar, Camila Ribeiro
Nunes, Beatriz Vieira Coelho
Sassaki, Betina da Silva
Vasconcelos, Mariana dos Santos
de Oliveira, Lucivalda Pereira Magalhaes
Lyra, Andre Castro
Bueno, Allain Amador
de Jesus, Rosangela Passos
TRIALS, 2023, 24 (01)
[9] Efficacy of silymarin in patients with non-alcoholic fatty liver disease — the Siliver trial: a study protocol for a randomized controlled clinical trial
Camila Ribeiro de Avelar
Beatriz Vieira Coelho Nunes
Betina da Silva Sassaki
Mariana dos Santos Vasconcelos
Lucivalda Pereira Magalhães de Oliveira
André Castro Lyra
Allain Amador Bueno
Rosângela Passos de Jesus
Trials, 24
[10] A randomized controlled trial of kalmegh supplementation on non-alcoholic fatty liver disease
Nandekar, Sanket
Kumar, Sunil
Yadav, Devesh
Sen, Binay
Gadge, Pournima
JOURNAL OF HEPATOLOGY, 2023, 78 : S830 - S830

← 1 2 3 4 5 →